Central memory CD4 cells are an early indicator of immune reconstitution in HIV/AIDS patients with anti-retroviral treatment

Immunological Investigations

Volumn 41, Issue 1, 2012, Pages 1-14

  Hua, Wei ^a   Jiao, Yanmei ^a   Zhang, Hongwei ^a   Zhang, Tong ^a   Chen, Dexi ^a   Zhang, Yonghong ^a   Chen, Xinyue ^a   Wu, Hao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

ART; Central memory CD4 cells; Chronic HIV infection; Immune reconstitution

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC DISEASE; CLINICAL ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; MALE; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASYMPTOMATIC DISEASES; BIOMARKERS, PHARMACOLOGICAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; T-LYMPHOCYTE SUBSETS;

EID: 81555218168     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2011.576739     Document Type: Article

References (43)

1. 4+ T-cells despite suppression of HIV replication under HAART. AIDS Rev. 8:88-97.
2. 4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. J. Acquir. Immune Defic. Syndr. Dec 15;34(5):475-481.
3. 4+ T cells than increases in the number of cells. Immunology Nov;116(3):318-327.
4. 4+ T cells under successful highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 38:373-381.
5. 8+ T lymphocytes as a marker of residual virus replication in chronically HIV infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses 20:227-233.
6. Bostik, P., Noble, E. S., Mayne, A. E., Gargano, L., Villinger, F., Ansari, A. A. (2006). Central memory CD4 T cells are the predominant cell subset resistant to anergy in SIV disease resistant sooty mangabeys. AIDS 2006; 20:181-188.
7. 8+ T lymphocyte activation status and plasma HIV-RNA levels during antiretroviral therapy. AIDS 12: 1267-1273.
8. Bucy, R. P. (2004). Viral and cellular dynamics in HIV disease. Curr HIV/AIDS Rep. Apr;1(1):40-46. Review.
9. Cavert, W., Notermans, D. W., Staskus, K., Wietgrefe, S. W., Zupancic, M., Gebhard, K., Henry, K., Zhang, Z. Q., Mills, R., McDade, H., Schuwirth, C. M., Goudsmit, J., Danner, S. A., Haase, A. T. (1997). Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276: 960-964.
10. Clumeck, N., Pozniak, A., Raffi, F., the EACS Executive Committee (2008). European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. 2008 British HIV Association. HIVMed. 9: 65-71.
11. 4+ T cell responses in chronic HIV infection are not restored by antiretroviral therapy. J. Immunol. Aug 1;173(3):2184-2189.
12. Fritsch, R. D., Shen, X., Sims, G. P., Hathcock, K S., Hodes, R. J., Lipsky, P. E. (2005). Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J. Immunol. 175:6489-6497.
13. Ganesan, A., Chattopadhyay, P. K., Brodie, T. M., Qin, J., Gu, W., Mascola, J. R., Michael, N. L., Follmann, D. A., Roederer, M. (2010). Infectious Disease Clinical Research Program HIV Working Group. Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J. Infect. Dis. Jan 15;201(2):272-284.
14. Giorgi, J. V., Detels, R. (1989). T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin. Immunol. Immunopathol. 52: 10-18.
15. 4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. 6:904-912.
16. 4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J. Infect. Dis. 194:29-37.
17. 4+ T cell subsets. Virology 393(1):24-32.
18. Hirsch, H. H., Kaufmann, G., Sendi, P., Battegay, M. (2004). Immune reconstitution in HIV-infected patients. Clin. Infect. Dis. 38:1159-1166.
19. Hunt, P. W., Deeks, S. G., Rodriguez, B., Valdez, H., Shade, S. B., Abrams, D. I., Kitahata, M. M., Krone,M., Neilands, T. B., Brand, R. J., Lederman, M. M.,Martin, J. N. (2003). Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 17:1907-1915.
20. 4+ T cells and viremia: who's in control? Trends Immunol. 27(3):119-124.
21. 8+ T-cells negatively correlate with CD4 central memorycells in virally suppressed HIV-1-infected individuals. AIDS 22(15):1937-1941.
22. Kaufmann, G. R., Perrin, L., Pantaleo, G., Opravil, M., Furrer, H., Telenti, A., Hirschel, B., Ledergerber, B., Vernazza, P., Bernasconi, E., Rickenbach, M., Egger, M., Battegay, M. (2003). Swiss HIV Cohort Study Group. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch. Intern. Med. 163: 2187-2195.
23. Kaufmann, G. R., Zaunders, J., Cooper, D. A. (1999). Immune reconstitution in HIV- 1 infected subjects treated with potent antiretroviral therapy. Sex Transm Infect. 75(4): 218-224.
24. Lambotte, O., Demoustier, A., de Goër, M. G., Wallon, C., Gasnault, J., Goujard, C., Delfraissy, J. F., Taoufik, Y. (2002). Persistence of replication-competent HIV in both memory and naive CD4 T cell subsets in patients on prolonged and effective HAART. AIDS 16(16):2151-2157.
25. Landay, A., da Silva, B. A., King, M. S., Albrecht, M., Benson, C., Eron, J., Glesby, M., Gulick, R., Hicks, C., Kessler, H., Murphy, R., Thompson,M., White, A. C. Jr.,Wolfe, P., McMillan, F. I., Hanna, G. J. (2007). Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin. Infect. Dis. 44:749-754.
26. Lederman, M. M., Valdez, H. (2011). Immune restoration with antiretroviral therapies: implications for clinical management. JAMA 305(7):645-732.
27. Letvin, N. L., Mascola, J. R., Sun, Y., Gorgone, D. A., Buzby, A. P., Xu, L., Yang, Z. Y., Chakrabarti, B., Rao, S. S., Schmitz, J. E., Montefiori, D. C., Barker, B. R., Bookstein, F. L., Nabel, G. J. (2006). Preserved CD4R central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312:1530-1533.
28. Muñoz-Calleja, C., Costantini, A., Silvestri, G., Butini, L., Regnery, C. M., Mancini, S., Montroni, M. (2001). Highly active antiretroviral therapy induces specific changes in effector and central memory T cell sub-populations. AIDS 15:1887-1890.
29. 4+ central memory T cell decline results in CD4R effector memory insufficiency and overt disease in chronic SIV infection. J. Exp. Med. 204:2171-2185.
30. 8+ T cells correlate with plasma HIV-1 RNA level in HIV-1 infection. J. Infect. Dis. 178:1279-1287.
31. Pakker, N. G., Notermans, D. W., de Boer, R. J., Roos, M. T., de Wolf, F., Hill, A., Leonard, J. M., Danner, S. A.,Miedema, F., Schellekens, P. T. (1998). Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nat. Med. 4:208-214.
32. Panel on Antiretroviral Guidelines for Adults and Adolescents (2009). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. Available at .
33. Potter, S. J., Lacabaratz, C., Lambotte, O., Perez-Patrigeon, S., Vingert, B., Sinet, M., Colle, J. H., Urrutia, A., Scott-Algara, D., Boufassa, F., Delfraissy, J. F., Theze, J., Venet, A., Chakrabarti, L. A. (2007). Preserved central memory and activated effector memory CD4R T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J. Virol. 81: 13904-13915.
34. Robbins, G. K., Spritzler, J. G., Chan, E. S., Asmuth, D. M., Gandhi, R. T., Rodriguez, B. A., Skowron, G., Skolnik, P. R., Shafer, R. W., Pollard, R. B.; AIDS Clinical Trials Group 384 Team (2009). Incomplete Reconstitution of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384. Clin. Infect. Dis. 48:350-361.
35. Sallusto, F., Geginat, J., Lanzavecchia, A. (2004). Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22:745-763
36. Sallusto, F., Lenig, D., Förster, R., Lipp, M., Lanzavecchia, A. (1999). Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-771.
37. Sester, U., Sester, M., Köhler, H., Pees, H. W., Gärtner BC, Wain-Hobson S, Bocharov GMeyerhans A. Maintenance of HIV-specific central and effector memory CD4 and CD8 T cells requires antigen persistence. AIDS Res Hum Retroviruses. 2007Apr;23(4):549-53.
38. 8+ effector and memory T cell generation. Nat. Rev. Immunol. 4:835-842.
39. Williams, M. A., Bevan, M. J. (2007). Effector and memory CTL differentiation. Annu. Rev. Immunol. 25:171-192.
40. Wu, C. Y., Kirman, J. R., Rotte, M. J., et al. (2002). Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat. Immunol. 3: 852-858.
41. Zanetti, M., Franchini, G. T. (2006). T cell memory and protective immunity by vaccination: is more better? Trends Immunol. 27:511-517.
42. Zaph, C., Uzonna, J., Beverley, S. M., Scott, P. (2004). Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. 10:1104-1110.
43. Zhou, H. Y., Zheng, Y. H., Zhang, C. Y., Chen, J., He, Y., Ding, P. P., Li. H. (2007). Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years. Viral Immunol. 20(1):180-187.